SAN DIEGO and PARSIPPANY, N.J., Dec. 4, 2014 /PRNewswire/ -- Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, and Daiichi Sankyo, Inc. today announced acceptance of three abstracts with preliminary data highlighting Ambit's lead drug candidate, quizartinib. Presentations of the final data will be made during the 56 ASH Annual Meeting at the Moscone Center in San Francisco, CA on December 6-9, 2014.
http://ift.tt/1tUIwRb
http://ift.tt/1tUIwRb
No comments:
Post a Comment